Press Releases Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2026-05-13 pm EDT			5-day change	1st Jan Change
3.730 ^USD	-8.35%		-9.25%	-39.35%

May. 05	Myriad Genetics, Inc., Q1 2026 Earnings Call, May 05, 2026
May. 05	Myriad Genetics, Inc. Reiterates Earnings Guidance for the Full Year 2026	CI

Press Releases

May. 07	Myriad Genetics : to Participate in Upcoming Investor Healthcare Conferences	PU
May. 07	Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences	GL
May. 05	Myriad: Q1 Earnings Snapshot	AQ
May. 05	Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business	GL
May. 01	Myriad Genetics National Survey, 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan	AQ
Apr. 30	Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan	GL
Apr. 28	Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026	GL
Apr. 16	Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026	GL
Apr. 14	Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan	GL
Apr. 14	Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan	AQ
Apr. 09	Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting	GL
Mar. 17	Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer	GL
Mar. 02	Myriad Commercially Launches Precise MRD with Select Community Oncologists	GL
Feb. 24	Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests	GL
Feb. 23	Myriad: Q4 Earnings Snapshot	AQ
Feb. 23	Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution	GL
Feb. 19	FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test	GL
Feb. 16	Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026	GL
Jan. 27	Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data	GL
Jan. 12	Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance	GL
Jan. 05	Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference	GL
Dec. 09	Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium	GL
Nov. 25	Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health	GL
Nov. 11	Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences	GL
Nov. 10	Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs	GL